Tissue, cell and stage specificity of (epi)mutations in cancers
- 1 August 2005
- journal article
- Published by Springer Nature in Nature Reviews Cancer
- Vol. 5 (8) , 649-655
- https://doi.org/10.1038/nrc1674
Abstract
Most (epi)mutations in cancers are specific to particular tumours or occur at specific stages of development, cell differentiation or tumorigenesis. Simple molecular mechanisms, such as tissue-restricted gene expression, seem to explain these associations only in rare cases. Instead, the specificity of (epi)mutations is probably due to the selection of a restricted spectrum of genetic changes by the cellular environment. In some cases, the resulting functional defects might be constrained to be neither too strong nor too weak for tumour growth to occur; that is, they lie within a 'window' that is permissive for tumorigenesis.Keywords
This publication has 62 references indexed in Scilit:
- Cadherin-mediated cell–cell adhesion: sticking together as a familyCurrent Opinion in Structural Biology, 2003
- RecQ helicases: caretakers of the genomeNature Reviews Cancer, 2003
- Inherited variants of MYH associated with somatic G:C→T:A mutations in colorectal tumorsNature Genetics, 2002
- APC Mutations in Sporadic MedulloblastomasPublished by Elsevier ,2000
- Activation of β-catenin in epithelial and mesenchymal hepatoblastomasOncogene, 2000
- The Hallmarks of CancerCell, 2000
- Mutations of the β‐Catenin Gene in Endometrial CarcinomasJapanese Journal of Cancer Research, 1999
- β-Catenin mutations in cell lines established from human colorectal cancersProceedings of the National Academy of Sciences, 1997
- Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomasNature Genetics, 1997
- A genetic model for colorectal tumorigenesisCell, 1990